BioXcel Gets Nod For $125M Bankruptcy Sale To Teva

By Emily Lever · October 21, 2026, 2:09 PM EDT

A Delaware bankruptcy judge Wednesday gave the OK to artificial intelligence-powered pharmaceutical group BioXcel to proceed with a $125 million sale to Israeli drugmaker Teva Pharmaceuticals, and allowed the debtor to...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

BioXcel Therapeutics, Inc.

Case Number

1:26-bk-11360

Court

Delaware

Nature of Suit

Date Filed

August 27, 2026